Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

  • Awaiting development
  • GID-TA11607
  • Expected publication date: 

26965-Bemarituzumab-Chemotherapy-for-Gastric-or-Gastro-Oesophageal-Junction-Cancer-V1.0-JUNE2024-NON-CONF.pdf (nihr.ac.uk)